• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Wave Life Sciences Second Quarter 2024 Financial Results Scheduled for August 8, 2024

    8/1/24 8:30:00 AM ET
    $WVE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $WVE alert in real time by email

    CAMBRIDGE, Mass., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will host a live webcast and conference call at 8:30 a.m. ET on Thursday, August 8, 2024, to review the company's second quarter 2024 financial results and provide business updates.

    The webcast and conference call may be accessed by visiting "Investor Events" on the investors section of the Wave Life Sciences website: ir.wavelifesciences.com/events-publications/events.

    Analysts planning to participate during the Q&A portion of the live call can join the conference call at the following audio conferencing link: available here. Once registered, participants will receive the dial-in information.

    Following the live event, an archived version of the webcast will be available on the Wave Life Sciences website.

    About Wave Life Sciences

    Wave Life Sciences (NASDAQ:WVE) is a biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health. Wave's RNA medicines platform, PRISM®, combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes editing, splicing, RNA interference and antisense silencing, providing Wave with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology. Wave's diversified pipeline includes clinical programs in Duchenne muscular dystrophy, Alpha-1 antitrypsin deficiency and Huntington's disease, as well as a preclinical program in obesity. Driven by the calling to "Reimagine Possible", Wave is leading the charge toward a world in which human potential is no longer hindered by the burden of disease. Wave is headquartered in Cambridge, MA. For more information on Wave's science, pipeline and people, please visit www.wavelifesciences.com and follow Wave on X (formerly Twitter) and LinkedIn.  

    Investor Contact:

    Kate Rausch

    +1 617-949-4827

    [email protected]

    Media Contact:

    Alicia Suter

    +1 617-949-4817

    [email protected]



    Primary Logo

    Get the next $WVE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $WVE

    DatePrice TargetRatingAnalyst
    6/11/2025$14.00Outperform
    Raymond James
    4/29/2025$10.00Overweight
    Cantor Fitzgerald
    4/8/2025$18.00Outperform
    Wedbush
    2/25/2025$26.00Buy
    Jefferies
    10/16/2024$22.00Outperform → Strong Buy
    Raymond James
    9/27/2024$10.00 → $13.00Overweight
    JP Morgan
    9/19/2024$11.00Buy
    B. Riley Securities
    9/9/2024$10.00Overweight
    JP Morgan
    More analyst ratings